CyFlow™ c-Myc Biotin
| Antibody: | Yes |
| Antigen: | c-Myc |
| Application: | Flow cytometry |
| Clonality: | monoclonal |
| Clone: | 9E10 |
| Field of Interest: | Epitope tags |
| Format/Fluorochrome: | Biotin |
| Isotype: | IgG1 |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Fusion Proteins, Human |
| Product number: | AJ852400 |
For Research Use Only
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | Synthetic peptide sequence (AEEQKLISEEDLL) corresponding to the C-terminal region of human c-Myc |
| Usage | The reagent is designed for indirect immunofluorescence analysis by Flow Cytometry. Working concentrations should be determined by the investigator. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Persson H, Hennighausen L, Taub R, DeGrado W, Leder P: Antibodies to human c‑myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science. 1984 Aug 17; 225(4663):687‑93. < PMID: 6431612 > | Evan GI, Lewis GK, Ramsay G, Bishop JM: Isolation of monoclonal antibodies specific for human c‑myc proto‑oncogene product. Mol Cell Biol. 1985 Dec; 5(12):3610‑6. < PMID: 3915782 > | Spandidos DA, Pintzas A, Kakkanas A, Yiagnisis M, Mahera H, Patra E, Agnantis NJ: Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res . 1987; 7(6):1299‑304. < PMID: 3327455 > | Siegel J, Brandner G, Hess RD: Cross‑reactivity of the monoclonal antibody 9E10 with murine c‑MYC. Int J Oncol. 1998 Dec; 13(6):1259‑62. < PMID: 9824641 > | Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D, Zeller K: Function of the c‑Myc oncogenic transcription factor. Exp Cell Res. 1999; 253(1):63‑77. < PMID: 10579912 > | Prendergast GC: Mechanisms of apoptosis by c‑Myc. Oncogene . 1999; 18(19):2967‑2987. < PMID: 10378693 > | Boxer LM, Dang CV: Translocations involving c‑myc and c‑myc function. Oncogene. 2001; 20(40):5595‑5610. < PMID: 11607812 > | Hilpert K, Hansen G, Wessner H, Kuttner G, Welfle K, Seifert M, Hohne W: Anti‑c‑myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Eng. 2001 Oct; 14(10):803‑6. < PMID: 11739900 > | Hoffman B, Amanullah A, Shafarenko M, Liebermann DA: The proto‑oncogene c‑myc in hematopoietic development and leukemogenesis. Oncogene. 2002; 21(21):3414‑3421. < PMID: 12032779 > | Cermák L, Símová S, Pintzas A, Horejsí V, Andera L: Molecular mechanisms involved in CD43‑mediated apoptosis of TF‑1 cells: Roles of transcription Daxx expression, and adhesion molecules. J Biol Chem. 2002 Mar 8; 277(10):7955‑61. < PMID: 11773067 > | Baggio R, Burgstaller P, Hale SP, Putney AR, Lane M, Lipovsek D, Wright MC, Roberts RW, Liu R, Szostak JW, Wagner RW: Identification of epitope‑like consensus motifs using mRNA display. J Mol Recognit. 2002 May-Jun; 15(3):126‑34. < PMID: 12203838 > | Fujiwara K, Poikonen K, Aleman L, Valtavaara M, Saksela K, Mayer BJ: A single‑chain antibody/epitope system for functional analysis of protein‑protein interactions. Biochemistry. 2002 Oct 22; 41(42):12729‑38. < PMID: 12379115 > | Wang X, Campoli M, Ko E, Luo W, Ferrone S: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti‑tag monoclonal antibodies. J Immunol Methods. 2004 Nov; 294(1‑2):23‑35. < PMID: 15604013 > | Veracini L, Simon V, Richard V, Schraven B, Horejsi V, Roche S, Benistant C: The Csk‑binding protein PAG regulates PDGF‑induced Src mitogenic signaling via GM1. J Cell Biol. 2008 Aug 11; 182(3):603‑14. < PMID: 18695048 > | Jelínková I, Šafaříková B, Blanářová OV, Skender B, Hofmanová J, Sova P, Moyer MP, Kozubík A, Kolář Z, Ehrmann J, Vaculová AH: Platinum (IV) complex LA‐12 exerts higher ability than cisplatin to enhance TRAIL‐induced cancer cell apoptosis via stimulation of mitochondrial pathway. Biochem pharmacology. 2014 Dec 1; 92(3):415‐24. < PMID: 25285768 >